

**Sangamo BioSciences, Inc.**  
Point Richmond Tech Center  
501 Canal Blvd., Suite A100  
Richmond, CA 94804  
510-970-6000 • 510-236-8951(Fax)

---

**SANGAMO BIOSCIENCES ANNOUNCES THIRD-QUARTER 2002  
TELECONFERENCE**

**Richmond, California** – October 23, 2002 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third-quarter financial results on Wednesday, October 30, 2002 after the market closes. The announcement will be followed by a conference call at 2:00 p.m. PST, which will be open to the public. During the conference call, the company will review its progress during the third quarter.

The conference call dial-in numbers are 800-730-7991 for domestic callers and 706-634-7552 for international callers. For those unable to listen in at the designated time, a conference call replay will be available for 1 week following the conference call, from approximately 6:00 p.m. PST on October 30, 2002 to 12:00 midnight PST on November 6, 2002. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291, respectively. The conference ID number for the replay is 6307446.

**About Sangamo**

Sangamo BioSciences, Inc., of Richmond, CA, is focused on the research and development of novel transcription factors for the regulation of gene expression. The company's most advanced therapeutic development program involves the use of transcription factors for the treatment of cardiovascular disease. Other therapeutics development programs are focused on cancer, neuropathic pain, ophthalmic and infectious diseases. Sangamo's proprietary technology enables the engineering of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company is developing ZFP TFs as a fundamentally enabling technology for commercial applications in human therapeutics, pharmaceutical discovery, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFP TFs. For more information about Sangamo, visit the company's web site at [www.sangamo.com](http://www.sangamo.com).

*This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.*

Contact: Elizabeth Wolffe, Ph.D.  
**Sangamo BioSciences, Inc.**  
510-970-6000, x271  
[ewolffe@sangamo.com](mailto:ewolffe@sangamo.com)

###

**Sangamo BioSciences, Inc.**  
Point Richmond Tech Center  
501 Canal Blvd., Suite A100  
Richmond, CA 94804  
510-970-6000 • 510-236-8951(Fax)

---